Direct compression of levofloxacin hemihydrate into immediate-release tablet cores is evaluated through a risk-based design space where the primary response variables are disintegration time, dissolution at 30 minutes in 900 mL of 0.1 M hydrochloric acid according to USP <711>, and content uniformity according to USP <905>. The hemihydrate salt contributes approximately 512.4 mg per 500 mg levofloxacin base dose, and 768.7 mg per 750 mg base dose; when total core mass ranges from 700 mg to 950 mg for the 500 mg strength, the active fraction lies between 54 % w/w and 73 % w/w, which shifts the blend toward a compaction regime in which excipient plasticity and moisture sorption dominate tablet hardness. With a D90 particle size below 250 µm and a bulk density above 0.38 g/cm³ measured by USP <616> Method I, direct compression can run on an 8-station or 16-station rotary press at turret speeds of 25–55 min⁻¹, with precompression force set at 1.5–3.0 kN and main compression force between 8 kN and 18 kN; however, when bulk density falls below 0.35 g/cm³, die fill variation produces weight variability exceeding ±3 % on rotary equipment, and published data for this specific configuration is limited. Industry compliance for such a blend is anchored to ICH Q6A decision tree #4 for particle size control, USP <905> for dosage unit uniformity, USP <616> for bulk and tapped density, USP <701> for disintegration, and FDA 21 CFR 211.110 for in-process sampling and testing; ICH Q3C and ICH Q3D set residual solvent and elemental impurity thresholds, with the parenteral daily intake limits in ICH Q3D Table A.1 applied when the same API lot is designated for injectable finishing. The downstream production process is high-shear blending of API with microcrystalline cellulose, crospovidone, and magnesium stearate in a bin blender at 10–15 RPM for 12–18 minutes, followed by compression to a mean hardness of 8–12 kp and film coating with a polyvinyl alcohol or hydroxypropyl methylcellulose system that adds 2.0–3.5 % w/w to core mass. Finished product configurations are round, biconvex, film-coated immediate-release tablets at 250 mg, 500 mg, and 750 mg base strengths; terminal packaging is typically PVC/PVDC/aluminum blister or HDPE bottle with desiccant, and because the API contains hemihydrate lattice water, direct compression is generally run without pre-drying unless ambient relative humidity exceeds 60 %, at which point hopper bridging and sticking to punch faces have been observed in production-scale batches.

Why does wet granulation of a 750 mg levofloxacin hemihydrate formulation shift the fluid-bed endpoint at 52–58°C?

Because the hemihydrate lattice water begins to desorb above approximately 60 °C, high-shear wet granulation of a 750 mg strength requires a drying protocol that maintains product temperature below 50 °C while still reducing free moisture below 2.0 % w/w as measured by loss on drying. The formulation input for each tablet is 768.7 mg levofloxacin hemihydrate; when the granulated core mass is controlled at 1200–1350 mg before coating, the active fraction is approximately 57–64 % w/w, which places the batch inside a high-dose regime where binder level and wet massing time strongly affect tablet disintegration. The production process uses a high-shear granulator with a 150 L bowl, impeller speed 120–200 rpm, chopper speed 1500–3000 rpm, and purified water addition at 8–12 % w/w of the dry powder mass; wet massing time is held between 3 minutes and 7 minutes because over-massing produces dense granules that retain fine-particle acicular API and delay dissolution. Drying is performed in a fluid-bed dryer with inlet air temperature at 65 °C and constant product temperature monitoring at 42–48 °C; endpoint is not determined by time alone but by in-process loss on drying combined with USP <921> Method Ia water content, where the theoretical hemihydrate lattice water contribution is 2.43 % w/w and total water content should not fall below that value during drying. Compliance for this high-dose wet granulation route is covered by ICH Q6A decision tree #3 for polymorphism and hydrate form, ICH Q3C for residual solvent control when binder is prepared with alcohol, ICH Q3D for elemental impurities, and FDA 21 CFR 211.65 for equipment design and cleaning; process validation batches are expected to include X-ray powder diffraction and differential scanning calorimetry to confirm that the hemihydrate phase remains unchanged after drying. The finished product types are scored, film-coated immediate-release tablets at 750 mg base strength, sometimes split into half-tablet regimens of 375 mg base equivalent; these tablets are packaged in unit-dose blisters or HDPE bottles with desiccant. Operational boundaries include a strict product temperature limit of 50 °C during drying, avoidance of fluid-bed outlet relative humidity above 60 %, and exclusion of highly hygroscopic binders that would require extended drying at the dehydration threshold of the hemihydrate lattice.

Capsule filling with levofloxacin hemihydrate at 250 mg base strength differs from tablet compression because the needle-like or rod-shaped particle habit of the API tends to produce static adhesion to gelatin capsule inner walls when relative humidity drops below 30 %. The hemihydrate input is 256.2 mg per 250 mg capsule, and the total fill weight is typically 340–420 mg depending on choice of lactose, pregelatinized starch, or microcrystalline cellulose as the diluent; this produces a capsule fill density that is sensitive to powder bed aeration and requires either a dosator or tamping-pin machine with vacuum-assisted die filling. Compliance for this route falls under USP <1174> for powder flow, USP <616> for bulk and tapped density, USP <905> for content uniformity, USP <711> for dissolution of filled capsules, and ICH Q3C/Q3D for residual solvent and elemental impurity control; batch documentation should also reference FDA 21 CFR 211.110 for in-process fill weight verification. The production process consists of sieving the API through a 0.8 mm screen, blending the API and diluents in a low-shear tumble blender at 10–15 RPM for 15–20 minutes, then filling into size 0 or size 1 hard gelatin or HPMC capsules; fill weight is checked every 15–20 minutes with a tolerance of ±3 %, and empty shells are pre-conditioned at 40–50 % RH to prevent embrittlement or swelling. Finished product types are opaque hard capsules at 250 mg and 500 mg base strengths, typically packaged in aluminum-aluminum blisters to limit moisture ingress; the 500 mg capsule uses 512.4 mg hemihydrate per unit and may require a larger size 0 shell with tapped density control above 0.50 g/cm³ to achieve complete fill without overcompression of the slug. The main operational limitation is the narrow humidity window: below 30 % RH, static charge increases fill weight variability, while above 60 % RH, gelatin shell softening and API-lubricant moisture uptake can reduce blend flow and delay dissolution.

When reconstituted granules require 5-day room-temperature stability, how does the hemihydrate lattice water influence pH after reconstitution?

For oral granule sachet applications, the unit dose is calibrated not by tablet compression but by reconstitution volume; a 500 mg base sachet contains 512.4 mg levofloxacin hemihydrate and is intended for dispersion in 100 mL of purified water to give a nominal 5 mg/mL suspension. The total sachet fill mass is typically 3–5 g because the formulation includes a dispersing agent such as hydroxypropyl methylcellulose, a sweetener such as mannitol or sorbitol, and a flavoring system; the hemihydrate active fraction in the dry fill is therefore approximately 10–17 % w/w, which is considerably lower than in tablets or capsules and permits uniform dispersion without high-shear mixing. The downstream production process uses fluid-bed granulation, where the API is preblended with the dry dispersion excipients and sprayed with a purified water or low-viscosity hypromellose binder solution; inlet air temperature is maintained at 55–65 °C, product temperature is kept below 45 °C, and the granules are dried to a loss-on-drying below 1.5 % w/w before sieving through a 1.0 mm screen. The finished granule material is filled into unit-dose aluminum-foil sachets under nitrogen or in a controlled humidity environment below 40 % RH; terminal product types are 250 mg and 500 mg base single-dose sachets that reconstitute to oral suspension, with the 250 mg sachet containing 256.2 mg hemihydrate and targeting 50 mL final volume. Compliance for this route includes ICH Q1A(R2) stability testing under zones III and IV, ICH Q3C for residual solvent, ICH Q3D for elemental impurities, and USP <905> for content uniformity of the filled sachets; dissolution testing after reconstitution is performed with USP <711> Apparatus II at 50 rpm in 0.1 M HCl. The pH after reconstitution is controlled between 5.0 and 6.0 because levofloxacin exhibits zwitterionic behavior and may precipitate or form aggregates at higher pH; therefore calcium carbonate or magnesium carbonate flavor buffers are avoided, and the granule matrix is designed without polyvalent cations that could chelate the fluoroquinolone. Published stability data for this specific room-temperature 5-day reconstituted configuration is limited, but the critical control point is the hydration state of the API during fluid-bed drying, which must not fall below the theoretical hemihydrate lattice water content of 2.43 % w/w to avoid post-reconstitution pH drift.

Sterile filtration pressure decay thresholds for 25 mg/mL levofloxacin injection concentrate with hemihydrate-derived free base

The production of a 25 mg/mL levofloxacin injection concentrate from levofloxacin hemihydrate begins with dispersion of 25.62 mg hemihydrate per mL in Water for Injection at 20–25 °C, followed by addition of dilute hydrochloric acid to form a soluble levofloxacin hydrochloride species in situ; the pH is then adjusted to 3.8–5.8 with sodium hydroxide, and the bulk solution is sparged with nitrogen to reduce oxidative discoloration. For ready-to-use 5 mg/mL injection, the hemihydrate input is 5.124 mg/mL, equivalent to 512.4 mg per 100 mL bag and 768.7 mg per 150 mL bag; this concentration is used in flexible PVC-free or polyolefin containers because levofloxacin can adsorb to polyvinyl chloride delivery systems. The process uses a closed jacketed stainless steel reactor with agitator speed 80–150 rpm, dissolution time 15–30 minutes, and a pre-filtration through 0.45 µm followed by terminal sterilizing grade filtration through 0.22 µm polyvinylidene fluoride membranes; filter integrity is verified by bubble point or pressure decay testing before and after filtration according to EU GMP Annex 1 and FDA 21 CFR 211.113(b). Aseptic filling is conducted under ISO 14644-1 Class 5 conditions with continuous particle monitoring, and the filled solution is subjected to sterility testing by USP <71>, bacterial endotoxin testing by USP <85> with a limit not exceeding 0.5 EU/mg, and particulate matter testing by USP <788>. Finished product types are ready-to-use infusion bags at 250 mg/50 mL, 500 mg/100 mL, and 750 mg/150 mL, and single-dose vials of 25 mg/mL concentrate intended for dilution before intravenous administration; the concentrate is often packed under nitrogen with a stopper design validated for needle-stick integrity. The main processing boundary is the pH-dependent solubility of the fluoroquinolone: above pH 6.0 the dissolved levofloxacin base can precipitate, while below pH 3.0 the solution becomes corrosive to unprotected stainless steel components; therefore dissolution and filling lines are specified with pharmaceutical-grade 316L stainless steel contact surfaces and pH probes calibrated at 3.00, 5.00, and 7.00 buffer points. The hemihydrate lattice water contribution must be accounted for in the mass balance, and the final bulk solution is held for no more than 8 hours at 20–25 °C before sterile filtration unless a validated extended hold time is established.